Clinical Trials Browser

Phase 2 × INDUSTRY × zimberelimab × Clear all

NCT04736173 2026-03-30

ARC-10

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05329766 2026-03-30

EDGE-Gastric

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 2 FDA

Metastatic Urothelial Cancer

NCT06727565 2026-03-02

VELOCITY-HNSCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts

Squamous Cell Carcinoma of Head and Neck

NCT05676931 2025-10-02

EDGE-Lung

Phase 2 Active not recruiting

Advanced Non-Small Cell Lung Cancer

NCT04262856 2025-08-26

ARC-7

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05177770 2025-05-08

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Terminated

16 enrolled 10 charts

Neoplasms, Prostatic Neoplasms

NCT06155396 2024-02-28

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT03972722 2019-06-05

CC

Phase 2 Unknown

Uterine Cervical Neoplasms